Navigation Links
Telik Announces Presentation at ASCO Annual Meeting
Date:5/21/2009

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL.

Details of the presentation are as follows:

           -- Abstract #5552 - General Poster Session, Gynecologic Cancer;
              Sunday, May 31, 2009, 2:00-6:00pm EDT; Level 2, West Hall C

              Title:  "Randomized phase III study of canfosfamide (C, TLK286)
              plus pegylated liposomal doxorubicin (PLD) versus PLD as
              second-line therapy in platinum (P) refractory or resistant
              ovarian cancer (OC)."

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
2. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
5. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
6. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
7. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
10. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
11. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
(Date:6/19/2013)... This news release is available in Spanish . ... the field of neglected diseases, it goes by the name ... health research was devoted to conditions that accounted for 90 ... counteract this imbalance that the Drugs for Neglected Diseases initiative ... anniversary year, the organization has been granted the BBVA Foundation ...
(Date:6/19/2013)... 19, 2013 The Movement ... neurosurgeons, psychiatrists and urologists with specialists in physical ... works with patients and their family members to ... of life. Patients also have the opportunity to ... research. , “Movement disorders can be relentlessly progressive ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 North ... announced organizational changes to advance development of its ... said, “To support the advanced development of our ... changes to the Company’s management structure and engaged ... The Company announced that Michael Galiger will serve ...
(Date:6/19/2013)... Monroe, OH (PRWEB) June 19, 2013 DiscountFurnaceFilter.com, ... is excited to offer the 5-2-1 Compressor Saver kit at ... a Hard Start Kit) aids the air conditioning unit during ... helping to prevent air compressor or unit burn out. , ... start up so the air conditioner uses less power to ...
(Date:6/19/2013)... Kansas City will host its first Ciclovia event on ... A section of Main Street in the midtown area will be ... event. The Main Street Corridor Development and BikeWalkKC ... City join the ranks of dozens of cities across the US ... community vibrancy and active lifestyles. , “Ciclovia is the perfect event ...
Breaking Medicine News(10 mins):Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3
... 2009 U.S. Sales Up 191% - , , - Total Net ... Conference Call to be Held Today at 3:30 pm Central Time - ... (Amex: UPI ), a medical device company that develops, manufactures ... results for the fourth quarter and full year ended March 31, 2009. ...
... Mass., June 4 PLC Systems Inc. (OTC Bulletin Board: ... device-based technologies, today announced the appointment of Louis Brenner, M.D. ... Senior Vice President at AMAG Pharmaceuticals, Inc., fills the seat ... , , Dr. Brenner, 39, brings to the PLC ...
... volunteers who led more than one million people in March for Babies ... of Dimes raise urgently needed funds for programs that help moms and ... a premature child, I know firsthand the toll that premature birth can ... supporting the March of Dimes," says Sherri Shepherd , ...
... research that has suggested excess weight worsens disease , THURSDAY, ... may not worsen asthma, as many experts have thought, but ... manage the chronic condition. , Inhaled corticosteroids are the most ... with asthma, many of whom are overweight or obese. , ...
... (NYSE: CBM ) announced today that it has ... the Company that it is in compliance with the revised ... on April 14, 2009, the Company had failed to meet ... over a consecutive 30-day period and total shareholders, equity had ...
... night, the America,s Health Insurance Plans (AHIP) Foundation paid ... Group Health Cooperative of South Central Wisconsin, and L.A. ... designed to improve the health and environment of communities ... health plans of working with local partners in a ...
Cached Medicine News:Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 3Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 4Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 5Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 6Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 7Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 8Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 9Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 10Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 11Health News:PLC Systems Announces Appointment of Louis Brenner, M.D. to Board of Directors 2Health News:Celebrities Lead One Million Walkers and Urge Public to Support March for Babies(R) 2Health News:Celebrities Lead One Million Walkers and Urge Public to Support March for Babies(R) 3Health News:Obesity May Dampen Response to Asthma Meds 2Health News:AHIP Foundation Announces 2009 Community Leadership Awards 2
Made exclusively from LactoSorb® Resorbable Copolymer....
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
... Stryker Conquest Suture Retrievers ... that pierce through soft ... through the tissue to ... Conquest Retrievers are front ...
... excising soft tissue more efficiently than a punch ... edge on the straight scissor helps to maintain ... jaws for more efficient resection.,The curved scissors, available ... perfect tools for ACL stump removal, meniscectomies and ...
Medicine Products: